Delivering Accelerated Market Access for Partner Therapeutics, 6 Months Ahead of Schedule
"Our collaboration was a unique situation given our company acquired a new oncolytic asset, then 2 days later the asset was approved by the FDA. We had very little time to prepare for launch. Thankfully the D2 Market Access team had already established relationships through their contractual agreement with the previous manufacturer. Their pre-indication exchange meetings with key population health decision makers were well prepared and executed, ultimately allowing customers to be well-prepared and knowledgeable of the product prior to launch."
Key Challenges
Time Constraints
With only two days between product acquisition and FDA approval, PTx had little time to prepare for launch. A traditional 9-12 month market access strategy was not an option.
Accessing Key Payer Decision Makers
Gaining immediate access to the appropriate decision makers at target payer organizations was critical. A slow or improper approach could have delayed patient access by months.
Establishing Favorable Medical Policy
For the product to be successful, PTX needed to secure favorable coverage and Medical Policy for Bizengri's approved prescribing information (PI) from key payers.
"I thought the market access team did a great job overall and it never felt as though this was a contract organization but an extension of our company. David Saunders did a great job as the D2 lead, understanding and executing our market access strategy while constantly communicating key learnings and insights from payer customers. The account team was very professional, responsive, and committed to delivering account management excellence as well. It was also great to have D2 senior leadership, Dean Erhardt, engaged throughout our collaboration as it felt D2 was entirely committed to our partnership.
I would recommend D2 Solutions as a purposeful partner for organizations needing market access strategy and account management execution, and reimbursement strategy."